Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Transgene S.A.
Perrigo doesn’t attempt to diminish significance of challenge to regain sales growth in formula market as it resets its plants. Analysts see formula business as only current impediment to stronger results.
Perrigo says 2024 results will be slowed by investment in companywide efficiency project including staff reductions. After Opill’s expected launch by late March, sales will be dilutive to earnings for the first year partly due to investments in the brand, primarily at retailers and online in Q2.
Like his previous move, Papa joins a pharma firm making a significant organizational shift to cut costs and increase revenues after extended period of higher spending and slowing income.
Aside from mixed earnings at major South Korean pharma firms, recent updates across the local industry have included the ongoing leadership dispute at Hanmi Group, the approval and reimbursement of Yuhan’s lazertinib as a first-line NSCLC therapy and the US approval of GC Biopharma’s immuno-globulin product.
- Gene Therapy, Cell Therapy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.